Aktieanalys

Optomed Q3 2023: Better than expected - Redeye

Redeye Publicerad: 03 Nov 2023 09:02

Redeye provides an initial take on Optomed’s Q3 2023 report. Sales during the quarter amounted to EUR4.2m (EUR3.7m) compared to our sales estimate of EUR4.0m. Moreover, EBIT came in at EUR-0.6m (EUR-1.4m), and the cash position at the end of the period amounted to EUR9.6m. Overall, the report was better than we anticipated, especially as cash flow from operating activities was positive during the quarter. We will provide a more in-depth update shortly, where we expect to only make minor changes in our estimates.

Länk till analysen i sin helhet: https://www.redeye.se/research/955369/optomed-q3-2023-better-than-expected?utm_source=finwire&utm_medium=RSS

Nyheter om Optomed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!